Safety and Efficacy of Endobronchial Valve for Bronchoscopic Lung Volume Reduction Surgery: a Prospective Pilot Study

Inclusion Criteria:

1. Patients with chronic obstructive pulmonary disease based on GOLD diagnosticcriteria;

2. Age range from 40 to 85 years old (including 40 and 85 years old);

3. BMI ≤ 35kg/m2;

4. 15% ≤ FEV1% pred ≤ 45%;

5. TLC>100% pred, RV>140% pred, and DLCO/red% ≥ 20%;

6. 100m ≤ 6WMD ≤ 500m after rehabilitation training;

7. Quit smoking for more than 4 months;

8. The evaluation result of pulmonary bypass ventilation function is negative;

9. Participants in this clinical trial requires the signing of an informed consentform by the individual or legal representative.

Exclusion Criteria:

1. Being pregnant or breastfeeding;

2. PaCO2>50mmHg and/or PaO2<45mmHg;

3. Obvious bronchiectasis or other infectious lung diseases;

4. Hospitalization due to pulmonary infection or acute exacerbation of COPD withinthe past 12 months prior to baseline assessment twice or more times;

5. Coagulation dysfunction, platelet count<60e+09/L;

6. Myocardial infarction or congestive heart failure within the past 24 weeks;

7. Previous lobectomy, LVRS or lung transplantation;

8. Anticoagulant therapy that cannot be stopped before surgery;

9. Uncontrolled pulmonary arterial hypertension (systolic pulmonary arterialpressure>45mmHg) or lungs diagnosed within the past 12 weeks Arterialhypertension;

10. Left ventricular ejection fraction (LVEF) within the past 12 weeks is less than 45%;

11. Pulmonary nodules that require intervention;

12. Patients participating in other clinical trials;

13. Individuals with other contraindications to bronchial operations;

14. Other circumstances that the researcher deems unsuitable for participation inthis clinical trial.